European Journal of Cancer
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
180:108-116.
2023
-
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4.
175:236-245.
2022
-
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
171:124-132.
2022
-
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
163:55-65.
2022
-
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
160:1-11.
2022
-
Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
156:127-137.
2021
-
Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update.
154:92-101.
2021
-
Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada.
151:126-135.
2021
-
Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer – A national cohort study.
145:71-80.
2021
-
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
142:132-140.
2021
-
Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer.
138:S12-S13.
2020
-
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
135:203-210.
2020
-
Current state of quality of life and patient-reported outcomes research.
121:55-63.
2019
-
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
108:69-77.
2019
-
Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study.
101:1-11.
2018
-
Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
91:38-46.
2018
-
C-statistic: A brief explanation of its construction, interpretation and limitations.
90:130-132.
2018
-
Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
85:31-38.
2017
-
Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
85:146-154.
2017
-
Corrigendum to “Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles” [Eur J Cancer 70 (2017) 62–74].
83:335-335.
2017
-
Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation.
80:63-72.
2017
-
Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).
72:192-199.
2017
-
Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles.
70:62-74.
2017
-
Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?.
70:143-145.
2017
-
Serotonergic antagonists target breast tumor-initiating cells in mouse models of human breast cancer.
69:S83-S83.
2016
-
Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence.
68:176-178.
2016
-
The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?.
68:173-175.
2016
-
Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.
59:65-78.
2016
-
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
56:85-92.
2016
-
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
51:2501-2507.
2015
-
1525 Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV): Efficacy and safety over multiple cycles of highly or moderately emetogenic chemotherapy.
51:S212-S213.
2015
-
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
51:1405-1414.
2015
-
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
51:685-696.
2015
-
Influence of censoring on conclusions of trials for women with metastatic breast cancer.
51:721-724.
2015
-
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.
50:3077-3088.
2014
-
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
50:706-712.
2014
-
Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin.
49:3537-3546.
2013
-
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study.
49:2621-2632.
2013
-
Symptom clusters in a population-based ambulatory cancer cohort validated using bootstrap methods.
48:3073-3081.
2012
-
357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors.
48:S147-S147.
2012
-
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
48:475-481.
2012
-
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
48:324-332.
2012
-
Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience.
48:353-359.
2012
-
Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: A perspective from Central America.
48:243-252.
2012
-
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial.
48:37-45.
2012
-
Early stopping rules in oncology: Considerations for clinicians.
47:2381-2386.
2011
-
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium.
47:1373-1379.
2011
-
Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation.
47:854-863.
2011
-
The unclear zone in phase II clinical trials.
46:2408-2413.
2010
-
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
45:2352-2359.
2009
-
Health-related quality of life of long-term childhood cancer survivors: A population-based study from the Childhood Cancer Registry of Piedmont, Italy.
43:2545-2552.
2007
-
Long term survivors of childhood cancer: Cure and care.
43:1778-1780.
2007
-
Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life.
43:1644-1645.
2007
-
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer.
43:660-675.
2007
-
Osteonecrosis in children and adolescents with cancer – An adverse effect of systemic therapy.
43:683-689.
2007
-
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.
42:1875-1880.
2006
-
Use of paediatric versus adult oncology treatment centres by adolescents 15–19 years old: the Canadian Childhood Cancer Surveillance and Control Program.
41:404-410.
2005
-
Economic evaluation of treatments for cancer in childhood.
40:1335-1345.
2004
-
The adolescent with cancer.
37:1523-1527.
2001
-
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival.
37:478-485.
2001
-
Can improved communication increase patient participation in randomised clinical trials?.
37:297-299.
2001
-
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer.
36:2329-2334.
2000
-
Response from D. Feeny, et al..
36:1460-1461.
2000
-
Tamoxifen for breast cancer prevention.
36:148-150.
2000
-
Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?.
35:1625-1627.
1999
-
FECS Board on retreat in Ireland.
35:528-528.
1999
-
Applicability of the Health Utilities Index to a Population of Childhood Survivors of Central Nervous System Tumours in the U.K..
35:256-261.
1999
-
Health-related quality of life in survivors of tumours of the central nervous system in childhood—a preference-based approach to measurement in a cross-sectional study1Presented in part to the meetings of the International Society of Pediatric Oncology (SIOP) in Paris, September 1994 and Montevideo, October 1995.1.
35:248-255.
1999
-
Detection of SYT–SSX1/2 fusion transcripts by reverse transcriptase–polymerase chain reaction (RT–PCR) is a valuable diagnostic tool in synovial sarcoma.
34:2087-2093.
1998
-
The prognostic role of gender in survival of adult cancer patients.
34:2271-2278.
1998
-
The prognostic role of gender in survival of adult cancer patients. EUROCARE Working Group..
34:2271-2278.
1998
-
Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.
34:1317-1333.
1998
-
A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer.
34:1008-1014.
1998
-
Osteopenia in children surviving brain tumours.
34:873-877.
1998
-
The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma.
34:31-36.
1998
-
Should alpha-interferon be included as standard treatment in multiple myeloma?.
34:22-24.
1998
-
Direct osteolysis induced by metastatic murine melanoma cells: Role of matrix metalloproteinases.
33:918-925.
1997
-
A survey of telomerase activity in human cancer.
33:787-791.
1997
-
Letter to the Editor: Comments on Health-related Quality of Life of Adults Surviving Malignancies in Childhood, Apajasalo et al., Eur J Cancer, 32A, No. 8, pp. 1354-1358, 1996.
33:506-507.
1997
-
An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer?.
32:1949-1956.
1996
-
Radiology in the detection and prevention of colorectal cancer.
31:1121-1126.
1995
-
The genetics of childhood cancer.
30:1942-1946.
1994
-
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
29:37-43.
1993
-
Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer.
29:21-23.
1993
-
Estrogen and progesterone receptor content of primary and secondary breast carcinoma: Influence of time and treatment.
23:819-826.
1987
-
Clinical significance of natural killer cell cytotoxicity: Need for proper data analysis in the design of clinical studies.
21:1287-1293.
1985
-
Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapy.
21:563-571.
1985
-
Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease.
20:1061-1068.
1984
-
The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma
2020
-
Viral sensitizers potential infection of cancer cells via NF-kappaB
2019
-
Expression of monoamine oxidase a is correlated with three-dimensional tumorsphere-formation by human breast tumor cells lines
2018
-
A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226)
2016
-
Tumour matrix stiffness regulates metastasis by promoting cancer cell interactions with the endothelium
2016
-
2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC
2015
-
3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
2015
-
3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
2015
-
5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry
2015
-
205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer
2014
-
508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041)
2014
-
1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2
2014
-
Predicting anthracycline benefit: TOP2A and CEP17-not only but also
2014
-
A cost-minimization analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, clexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma
2013
-
Difficulties in meeting accrual and obtaining adequate follow up in palliative trials: Results from an intergroup randomized trial of single vs multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20
2013
-
Prognostic risk stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy
2013
-
Simultaneous cone beam CT scans captured during prostate radiotherapy; image quality and the effect of arc delivery time
2013
-
607 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC
2012
-
239 The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein
2012
-
Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial
2012
-
Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial
2012
-
Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial
2012
-
Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor - First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747)
2012
-
Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors
2012
-
1314 POSTER Quality of Reporting of Modern Randomized Controlled Trials in Oncology
2011
-
3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups
2011
-
406 INVITED Stereotactic Radiotherapy for Liver Metastases
2011
-
6088 POSTER KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients
2011
-
Quality of Life in the ICON7 GCIG Phase III Randomised Clinical Trial
2011
-
Introduction
2006
-
Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours
2002
-
Phase II study of OSI-774 in patients with metastatic colorectal cancer
2002
-
How recruiting patients to clinical trials affects the doctor/patient relationship
2002
-
The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer
2002
-
Assessment of alternative and complimentary medicines and devices in cancer patients attending a multi-disciplinary cancer centre
1999
-
Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule
1999
-
p53 and WAF1 expression in epithelial ovarian cancer: Prognostic and predictive implications
1998
-
S28 GNRH analogues and ovarian ablation: How to integrate in the adjuvant strategy
1998
-
S35 CEF versus CMF in premenopausal women — Recent update
1998
-
Economic evaluation of chemotherapy with Mitoxantrone plus Prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints
1997
-
Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
1997
-
Liver metastases: Can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management?
1997
-
Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP)
1995
-
A model for the study of treatment response in human normal and tumour cells
1987
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)